Based on the Exelixis Inc stock forecast from 11 analysts, the average analyst target price for Exelixis Inc is USD 30.87 over the next 12 months. Exelixis Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Exelixis Inc is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Exelixis Inc’s stock price was USD 35.61. Exelixis Inc’s stock price has changed by +3.37% over the past week, +23.52% over the past month and +65.63% over the last year.
No recent analyst target price found for Exelixis Inc
No recent average analyst rating found for Exelixis Inc
Company Overview Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. Read Less
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who receiv...Read More
Frequently Asked Questions About Exelixis Inc (EXEL) Stock
Based on ratings from 11 analysts Exelixis Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 11 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on EXEL's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for EXEL is USD 30.87 over the next 12 months. The maximum analyst target price is USD 38 while the minimum anlayst target price is USD 26.
EXEL stock's Price/Earning ratio is 22.01.
Our analysis grades EXEL stock's Price / Earning ratio at F. This means that EXEL stock's Price/Earning ratio is above 74% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this EXEL may be a overvalued for its sector.
The last closing price of EXEL's stock was USD 35.61.
The most recent market capitalization for EXEL is USD 9.74B.
Based on targets from 11 analysts, the average taret price for EXEL is projected at USD 30.87 over the next 12 months.
This means that EXEL's stock price may go down by -13.32% over the next 12 months.
We can't find any ETFs which contains Exelixis Inc's stock.
As per our most recent records Exelixis Inc has 1,310 Employees.
Exelixis Inc's registered address is 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502.
You can get more information about it from Exelixis Inc's website at https://www.exelixis.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Exelixis Inc (EXEL) Stock
Based on ratings from 11 analysts Exelixis Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 11 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on EXEL's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for EXEL is USD 30.87 over the next 12 months. The maximum analyst target price is USD 38 while the minimum anlayst target price is USD 26.
EXEL stock's Price/Earning ratio is 22.01.
Our analysis grades EXEL stock's Price / Earning ratio at F. This means that EXEL stock's Price/Earning ratio is above 74% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this EXEL may be a overvalued for its sector.
The last closing price of EXEL's stock was USD 35.61.
The most recent market capitalization for EXEL is USD 9.74B.
Based on targets from 11 analysts, the average taret price for EXEL is projected at USD 30.87 over the next 12 months.
This means that EXEL's stock price may go down by -13.32% over the next 12 months.
We can't find any ETFs which contains Exelixis Inc's stock.
As per our most recent records Exelixis Inc has 1,310 Employees.
Exelixis Inc's registered address is 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502.
You can get more information about it from Exelixis Inc's website at https://www.exelixis.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for EXEL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
